cilengitide has been researched along with Disease Exacerbation in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clément, PM; Eisele, AC; Eisele, G; Krex, D; Neyns, B; Nikkhah, G; Ochsenbein, A; Picard, M; Schlegel, U; Simon, M; Stupp, R; Tabatabai, G; Tonn, J; Weller, M; Wick, A; Wick, W | 1 |
| Bethe, U; Brümmendorf, TH; Clement, PM; Delord, JP; Erfán, J; Gauler, TC; Hicking, C; Iglesias, L; Keilholz, U; Krauss, J; Mesía, R; Peyrade, F; Remenar, E; Schafhausen, P; Vermorken, JB | 1 |
| Ackland, S; Back, M; Buyse, ME; Kerestes, Z; Khasraw, M; Kichenadasse, G; Lee, A; McCowatt, S; Wheeler, H | 1 |
| Date, I; Ichikawa, T; Ishida, J; Kurozumi, K; Shimizu, T | 1 |
| Al-Hawary, M; Bradley, DA; Chen, A; Cooney, KA; Daignault, S; Dipaola, RS; Doyle, G; Escara-Wilke, J; Gross, ME; Hussain, M; Keller, ET; Mathew, P; Pienta, KJ; Ryan, CJ; Small, E; Smith, DC; Stein, MN | 1 |
| Bäuerle, T; Berger, MR; Goodman, SL; Komljenovic, D; Merz, M; Semmler, W | 1 |
| Agus, D; Alva, A; Carducci, M; Chen, A; Cooney, K; Daignault, S; Dipaola, R; Hussain, M; Pienta, K; Slovin, S; Smith, DC | 1 |
| Imaizumi, N; Kuonen, F; Monnier, Y; Rüegg, C | 1 |
| Akella, NS; Cloud, GA; Grossman, S; Hochberg, FH; Mikkelsen, T; Nabors, LB; Twieg, DB | 1 |
| Fittschen, C; Goodman, S; Jonczyk, A; Marshall, JF; Meyer, T; Mitjans, F; Piulats, J; Reyes, G | 1 |
1 review(s) available for cilengitide and Disease Exacerbation
| Article | Year |
|---|---|
Adhesion molecules and the extracellular matrix as drug targets for glioma.
Topics: Angiogenesis Inhibitors; Antibodies; Brain Neoplasms; Cell Adhesion Molecules; Disease Progression; Extracellular Matrix; Glioma; Humans; Molecular Targeted Therapy; Neoplasm Invasiveness; Neovascularization, Pathologic; Snake Venoms; Thalidomide; White Matter | 2016 |
6 trial(s) available for cilengitide and Disease Exacerbation
| Article | Year |
|---|---|
Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Snake Venoms; Temozolomide; Treatment Outcome | 2014 |
Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Snake Venoms; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2014 |
Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.
Topics: Adult; Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Therapy, Combination; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Procarbazine; Snake Venoms; Temozolomide; Treatment Failure; Tumor Suppressor Proteins; Young Adult | 2016 |
Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Collagen Type I; Disease Progression; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Peptides; Prostate-Specific Antigen; Prostatic Neoplasms; Snake Venoms; Time Factors; Treatment Outcome | 2011 |
Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Endothelial Cells; Humans; Infusions, Intravenous; Integrin alphaVbeta3; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplastic Cells, Circulating; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Vitronectin; Snake Venoms; Time Factors; Treatment Failure; United States | 2012 |
Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: quality and analysis results of a phase I trial.
Topics: Angiogenesis Inhibitors; Blood Flow Velocity; Blood Volume; Brain Neoplasms; Disease Progression; Echo-Planar Imaging; Glioblastoma; Glioma; Humans; Magnetic Resonance Angiography; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Peptides, Cyclic; Snake Venoms | 2004 |
3 other study(ies) available for cilengitide and Disease Exacerbation
| Article | Year |
|---|---|
Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study.
Topics: Animals; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Disease Progression; Female; Humans; Integrin alphaVbeta3; Magnetic Resonance Imaging; Mammary Neoplasms, Experimental; Rats; Rats, Nude; Receptors, Vitronectin; Snake Venoms; Tomography, X-Ray Computed | 2011 |
Radiation-induced modifications of the tumor microenvironment promote metastasis.
Topics: Angiogenesis Inhibitors; Cell Hypoxia; Cell Movement; Cell Proliferation; Cysteine-Rich Protein 61; Disease Progression; Endothelial Cells; Humans; Microvessels; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Receptors, Vitronectin; Snake Venoms; Tumor Microenvironment | 2011 |
In vivo therapy of malignant melanoma by means of antagonists of alphav integrins.
Topics: Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Antineoplastic Agents; Cell Adhesion; Cell Division; Disease Progression; Dose-Response Relationship, Drug; Growth Inhibitors; HT29 Cells; Humans; Integrins; Kinetics; Male; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Peptides, Cyclic; Receptors, Vitronectin; Snake Venoms; Tumor Cells, Cultured | 2000 |